Streptozotocin-induced diabetes in rats diminishes the size of the osteoprogenitor pool in bone marrow

Diabetes Research and Clinical Practice

Volumn 103, Issue 1, 2014, Pages 35-41

  Weinberg, E ^a   Maymon, T ^a   Moses, O ^a   Weinreb, M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Apoptosis; Bone marrow stromal cells; Diabetes; Oxidative stress

Indexed keywords

ALKALINE PHOSPHATASE; GLUCOSE; INSULIN; MALONALDEHYDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ADHESION; CELL COUNT; CELL POPULATION; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; HEMATOPOIETIC STEM CELL; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPROGENITOR CELL; OXIDATIVE STRESS; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; STROMA CELL;

APOPTOSIS; BONE MARROW STROMAL CELLS; DIABETES; OXIDATIVE STRESS;

ALKALINE PHOSPHATASE; ANIMALS; APOPTOSIS; BONE AND BONES; BONE DENSITY; BONE MARROW; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; FEMUR; LIPID PEROXIDATION; MALE; OSTEOBLASTS; OSTEOGENESIS; RATS; RATS, WISTAR; STEM CELLS;

EID: 84893661815     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.11.015     Document Type: Article

References (49)

1. Schwartz A.V. Diabetes mellitus does it affect boneα. Calcif Tissue Int 2003, 73(6):515-519.
2. Yamagishi S., Nakamura K., Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 2005, 65(6):1013-1015.
3. Verhaeghe J., van Herck E., Visser W.J., Suiker A.M., Thomasset M., Einhorn T.A., et al. Bone and mineral metabolism in BB rats with long-term diabetes. Decreased bone turnover and osteoporosis. Diabetes 1990, 39(4):477-482.
4. Hamada Y., Kitazawa S., Kitazawa R., Fujii H., Kasuga M., Fukagawa M. Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone 2007, 40(5):1408-1414.
5. Krakauer J.C., McKenna M.J., Buderer N.F., Rao D.S., Whitehouse F.W., Parfitt A.M. Bone loss and bone turnover in diabetes. Diabetes 1995, 44(7):775-782.
6. Funk J.R., Hale J.E., Carmines D., Gooch H.L., Hurwitz S.R. Biomechanical evaluation of early fracture healing in normal and diabetic rats. J Orthop Res 2000, 18(1):126-132.
7. Lu H., Kraut D., Gerstenfeld L.C., Graves D.T. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 2003, 144(1):346-352.
8. Takeshita F., Murai K., Iyama S., Ayukawa Y., Suetsugu T. Uncontrolled diabetes hinders bone formation around titanium implants in rat tibiae. A light and fluorescence microscopy, and image processing study. J Periodontol 1998, 69(3):314-320.
9. Figueroa-Romero C., Sadidi M., Feldman E.L. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 2008, 9(4):301-314.
10. Prasad A., Bekker P., Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease. Cardiol Rev 2012, 29(4):177-183.
11. Kim W., Hudson B.I., Moser B., Guo J., Rong L.L., Lu Y., et al. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann N Y Acad Sci 2005, 1043:553-561.
12. Manolagas S.C., Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007, 21(11):2605-2614.
13. Owen M. Lineage of osteogenic cells and their relationship to the stromal system. Bone and mineral research 1985, vol. 3:1-25. Elsevier, Amsterdam.
14. Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970, 3(4):393-403.
15. Friedenstein A.J., Deriglasova U.F., Kulagina N.N., Panasuk A.F., Rudakowa S.F., Luriá E.A., et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974, 2(2):83-92.
16. Maniatopoulos C., Sodek J., Melcher A.H. Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats. Cell Tissue Res 1988, 254(2):317-330.
17. Herbertson A., Aubin J.E. Dexamethasone alters the subpopulation make-up of rat bone marrow stromal cell cultures. J Bone Miner Res 1995, 10(2):285-294.
18. 2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro. J Endocrinol 2001, 168(1):131-139.
19. Tabuchi C., Simmons D.J., Fausto A., Russell J.E., Binderman I., Avioli L.V. Bone deficit in ovariectomized rats. Functional contribution of the marrow stromal cell population and the effect of oral dihydrotachysterol treatment. J Clin Invest 1986, 78(3):637-642.
20. Dresner-Pollak R., Gelb N., Rachmilewitz D., Karmeli F., Weinreb M. Interleukin 10-deficient mice develop osteopenia: decreased bone formation, and mechanical fragility of long bones. Gastroenterology 2004, 127(3):792-801.
21. Keila S., Pitaru S., Grosskopf A., Weinreb M. Bone marrow from mechanically unloaded rat bones expresses reduced osteogenic capacity in vitro. J Bone Miner Res 1994, 9(3):321-327.
22. 2 in young rats increases the osteogenic capacity of bone marrow. Bone 1997, 20(6):521-526.
23. Marie P.J. Human osteoblastic cells: a potential tool to assess the etiology of pathologic bone formation. J Bone Miner Res 1994, 9(12):1847-1850.
24. Bain S., Ramamurthy N.S., Impeduglia T., Scolman S., Golub L.M., Rubin C. Tetracycline prevents cancellous bone loss and maintains near-normal rates of bone formation in streptozotocin diabetic rats. Bone 1997, 21(2):147-153.
25. Shyng Y.C., Devlin H., Sloan P. The effect of streptozotocin-induced experimental diabetes mellitus on calvarial defect healing and bone turnover in the rat. Int J Oral Maxillofac Surg 2001, 30(1):70-74.
26. Kemink S.A., Hermus A.R., Swinkels L.M., Lutterman J.A., Smals A.G. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 2000, 23(5):295-303.
27. Gunczler P., Lanes R., Paz-Martinez V., Martins R., Esaa S., Colmenares V., et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab 1998, 11(3):413-419.
28. Locatto M.E., Abranzon H., Caferra D., Fernandez M.C., Alloatti R., Puche R.C. Growth and development of bone mass in untreated alloxan diabetic rats. Effects of collagen glycosylation and parathyroid activity on bone turnover. Bone Miner 1993, 23(2):129-144.
29. Botolin S., Faugere M.C., Malluche H., Orth M., Meyer R., McCabe L.R. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology 2005, 146(8):3622-3631.
30. Bouillon R., Bex M., Van Herck E., Laureys J., Dooms L., Lesaffre E., et al. Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 1995, 80(4):1194-1202.
31. Shires R., Teitelbaum S.L., Bergfeld M.A., Fallon M.D., Slatopolsky E., Avioli L.V. The effect of streptozotocin-induced chronic diabetes mellitus on bone and mineral homeostasis in the rat. J Lab Clin Med 1981, 97(2):231-240.
32. Lozano D., de Castro L.F., Dapía S., Andrade-Zapata I., Manzarbeitia F., Alvarez-Arroyo M.V., et al. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 2009, 150(5):2027-2035.
33. Botolin S., McCabe L.R. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 2007, 148(1):198-205.
34. Fowlkes J.L., Bunn R.C., Liu L., Wahl E.C., Coleman H.N., Cockrell G.E., et al. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 2008, 149(4):1697-1704.
35. Gao Y., Xue J., Li X., Jia Y., Hu J. Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells. J Pharm Pharmacol 2008, 60(12):1695-1700.
36. Molinuevo M.S., Schurman L., McCarthy A.D., Cortizo A.M., Tolosa M.J., Gangoiti M.V., et al. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res 2010, 25(2):211-221.
37. Motyl K.J., McCauley L.K., McCabe L.R. Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. J Cell Physiol 2012, 227(4):1326-1334.
38. Liang J., Chen H., Pan W., Xu C. Puerarin inhibits caspase-3 expression in osteoblasts of diabetic rats. Mol Med Rep 2012, 5(6):1419-1422.
39. Alikhani M., Alikhani Z., Boyd C., MacLellan C.M., Raptis M., Liu R., et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007, 40(2):345-353.
40. Mercer N., Ahmed H., Etcheverry S.B., Vasta G.R., Cortizo A.M. Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem 2007, 306(1-2):87-94.
41. Gopalakrishnan V., Vignesh R.C., Arunakaran J., Aruldhas M.M., Srinivasan N. Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochem Cell Biol 2006, 84(1):93-101.
42. Stolzing A., Coleman N., Scutt A. Glucose-induced replicative senescence in mesenchymal stem cells. Rejuvenation Res 2006, 9(1):31-35.
43. Weinberg E., Maymon T., Weinreb M. AGEs induce caspase-mediated apoptosis of rat BMSCs via TNFα production and oxidative stress. J Mol Endocrinol 2013, in press.
44. Ahmed N. Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res Clin Pract 2005, 67(1):3-21.
45. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 2011, 12(14):2096-2102.
46. Maiese K., Chong Z.Z., Shang Y.C. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 2007, 14(16):1729-1738.
47. Chen R.M., Wu G.J., Chang H.C., Chen J.T., Chen T.F., Lin Y.L., et al. 2,6-Di-isopropylphenol protects osteoblasts from oxidative stress-induced apoptosis through suppression of caspase-3 activation. Ann N Y Acad Sci 2005, 1042:448-459.
48. Hamada Y., Fujii H., Kitazawa R., Yodoi J., Kitazawa S., Fukagawa M. Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: a novel role of oxidative stress and therapeutic implications. Bone 2009, 44(5):936-941.
49. Mordwinkin N.M., Meeks C.J., Jadhav S.S., Espinoza T., Roda N., diZerega G.S., et al. Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow. Endocrinology 2012, 153(5):2189-2197.